Sustained virological response in patients with HCV treated with daclatasvir plus sofosbuvir, with or without ribavirin: a large, field-practice study

Rodolfo Sacco MD, PhD, Vincenzo Messina MD, Umberto Vespasiani Gentilucci MD, Luigi Elio Adinolfi MD, Antonio Ascione MD, Giorgio Barbarini MD, Angelo Barlattani MD, Giuseppe Cariti MD, Raffaele Cozzolongo MD, Basilio Fimiani MD, Ruggiero Francavilla MD, Caterina Furlan MD, Giovanni Garrucciu MD, Vincenzo Iovinella MD, Luca Rinaldi MD, Massimo Marignani MD, Paola Begini MD, Valeria Pace Palitti MD, Adriano M Pellicelli MD, Gaetano Scifo MD, Antonio Facciorusso MD, Luca Giacomelli PhD, Aashni Shah BSc, Gaetano Bertino MD, Serena Perazzo MD, Giampaolo Bresci MD, Antonio Izzi MD

Article Type

Original Research

Published

The aim of this retrospective, multicenter, field-practice study was to investigate the therapeutic efficacy and safety of the oral combination of daclatasvir and sofosbuvir, with or without ribavirin, in a large unselected cohort of patients with chronic hepatitis C virus infection.

Read more

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.